Biotech in brief
Tuesday, 02 December, 2008
Melbourne’s BioDiem has received another milestone payment from partner Nobilon for the duo’s intranasal flu vaccine agreement.
The payment of $1 million brings the total to $6 million in milestones from Nobilon, a subsidiary of Schering Plough.
BioDiem has licensed the majority of rights to its live attenuated influenza vaccine (LAIV) to Nobilon for overseas markets. Clinical trials are expected to begin next year.
Also flu-ridden, results from animal trials of Anadis antibody technology will be presented at the Australasian Society of Immunology conference in Canberra next week.
The trials, carried out by the University of Melbourne’s Professor Lorena Brown, involve topical application of bovine colostrum-derived virus antibodies on mucosal surfaces.
Anadis, which recently changed its name to Immuron, is developing the technology, called Flubody, to provide immune enhancement against influenza and bird flu.
Human trials are expected to begin next year.
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
